National Vision (EYE)
(Delayed Data from NSDQ)
$10.04 USD
+0.07 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.04 USD
+0.07 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Company News for Aug 13, 2021
by Zacks Equity Research
Companies In The News Are: CSIQ, DDS, EYE, AZEK
National Vision (EYE) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strength in Americas Best and Eyeglass World brands drove National Vision's (EYE) revenues in the second quarter of 2021.
National Vision (EYE) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 108.70% and 11.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
National Vision (EYE) is expected to report sequentially better results for the second quarter on gradual reopening of stores and return toward more normal operations.
National Vision (EYE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes
by Zacks Equity Research
National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.
OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology
by Zacks Equity Research
OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.
Inogen (INGN) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Inogen's (INGN) direct-to-customer business model and a strong product portfolio.
QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance
by Zacks Equity Research
According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.
NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes
by Zacks Equity Research
We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.
3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19
by Riya Anand
Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.
Medtronic (MDT) Reports Economic Findings on PRODIGY Data
by Zacks Equity Research
Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.
BD's (BDX) Digital Marketplace Set to Improve User Experience
by Zacks Equity Research
BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.
Philips (PHG)-Cognizant Collaborate to Develop Health Solutions
by Zacks Equity Research
Philips (PHG) is collaborating with Cognizant to develop health solutions that will help healthcare and life science companies provide improved patient care and accelerate clinical trial procedure.
McKesson (MCK) Enters Deal to Divest Some European Businesses
by Zacks Equity Research
McKesson (MCK) to sell off some of its European ventures to streamline its business and prioritize investments in areas where it has better expertise.
Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow
by Zacks Equity Research
Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.
Masimo (MASI) Reports Study Findings Backing the SedLine
by Zacks Equity Research
Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.
Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle
by Zacks Equity Research
Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle
Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.
Medtronic's (MDT) DEFINE AFib Study to Assess AF Burden
by Zacks Equity Research
Medtronic (MDT) begins first app-based study to understand atrial fibrillation burden in patients, utilizing data collected from the LINQ range of insertable cardiac monitors.
5 Top-Performing Liquid Stocks for Attractive Returns in 2021
by Zacks Equity Research
Here are five top-ranked liquid stocks -- Intuit (INTU), National Vision (EYE), Lindsay Corporation (LNN), Magnolia Oil & Gas (MGY) and Buckle (BKE) -- which investors can tap for attractive returns.
Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.
by Zacks Equity Research
Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.
West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about West Pharmaceutical's (WST) solid proprietary products segment.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.